ClinicalTrials.gg
TerminatedNCT03333746Updated May 30, 2019Results posted

Lenalidomide and Nivolumab in Treating Patients With Relapsed or Refractory Multiple Myeloma

A Phase 2 interventional study of Laboratory Biomarker Analysis and Lenalidomide in Recurrent Plasma Cell Myeloma and Refractory Plasma Cell Myeloma, sponsored by Yvonne Efebera. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-05-30.

Sponsored by Yvonne Efebera · Phase 2, Interventional, and Treatment

Why this study was terminated
Study was discontinued due to FDA recommendations of the potential toxicities of the combination of drugs.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 249 studies testing lenalidomide in Multiple Myeloma — 29 open to participants now, 70 under way, 14 of them phase 3. Lenalidomide · Multiple Myeloma.

Enrollment
234th of 249
1 · median 50
Started
2018
with 6 others
Phase 2
124 of 249
12 open now
Registered
169th of 249
by date

Among the 249 studies testing lenalidomide in Multiple Myeloma, this one is the 234th largest by enrollment, is one of 7 that started in 2018, is one of 124 in phase 2, and was the 169th registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

29 of the 249 studies testing lenalidomide in Multiple Myeloma are open now, in 12 countries. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

About lenalidomide

Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 586 Multiple Myeloma studies recruiting now, 431 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 249 studies testing lenalidomide in Multiple Myeloma, or all of them as a file.
02

Study summary

This phase II trial studies how well lenalidomide and nivolumab work in treating patients with multiple myeloma that has come back or does not respond to treatment. Drugs used in chemotherapy, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of cancer cells to grow and spread. Giving lenalidomide and nivolumab may work better in treating patients with multiple myeloma.

Read the detailed description

PRIMARY OBJECTIVES:

I. To determine the efficacy of nivolumab in combination with lenalidomide (Revlimid) in terms of overall response rate in patients with relapse/refractory multiple myeloma (MM).

OUTLINE:

Patients receive lenalidomide orally (PO) on days 1-21 and nivolumab intravenously (IV) over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up for 30 days.

03

Conditions studied

  • Recurrent Plasma Cell Myeloma
  • Refractory Plasma Cell Myeloma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with evidence of relapse or disease as defined by International Myeloma Working Group (IMWG) criteria and as defined by any of the following:

    • Serum m-protein >= 0.5 g/dl (>= 10 g/l)
    • Urine monoclonal protein >= 200 mg/24 hour(h)
    • Involved free light chain (FLC) level >= 10mg/dl (>= 100mg/l) and an abnormal serum free light chain ratio (\< 0.26, or > 1.65)
    • Measurable proven plasmacytoma (should be measured within 28 days of initial agent dosing)
  • Patients must have had at least 2
  • Patients must not have had progression of disease on lenalidomide 25 mg; stable disease on lenalidomide is permitted
  • Patient may be enrolled at any time from last line of therapy
  • Patients must have (ANC) > 1000/uL
  • >= 75,000/uL, if plasma cell percentage on bone marrow biopsy aspirate or core is > 30%, platelet eligibility requirement will be adjusted to 60,000/ul
  • Total =\< 1.5 mg/dL
  • Alkaline phosphatase =\< 3 X the (ULN)
  • (AST)/alanine aminotransferase (ALT) =\< 2 X the ULN
  • Patients must have adequate renal function as evidenced by serum creatinine =\< 2 mg/dL or calculated of >= 40 ml/min within 14 days of registration using Modification of Diet in Renal Disease () formula
  • Patient must be able to swallow capsule or tablet
  • Patients must provide
  • Patients must have a > 30%, no uncontrolled arrhythmias or class III-IV heart failure
  • Patients must have a performance status >= 70
  • A negative pregnancy test will be required for all women of child bearing potential; breast feeding is not permitted
  • Fertility requirements

    • Female patients with child bearing potential must have a negative pregnancy test at least 7 days before starting treatment drugs
    • Male patients must agree to use an adequate method of for the duration of the study and for 7 months afterwards
    • Female patients must be either posy-menopausal, free from menses >= 2 years (yrs), surgically sterilized, willing to use two adequate barrier methods of contraception to prevent pregnancy, or agree to abstain from sexual activity starting from screening and for 5 months afterwards
    • Female patients of child bearing potential must agree to comply with the fertility and pregnancy test requirements dictated by the Rev-Assist program

Exclusion criteria

Exclusion Criteria:

  • Patients with peripheral neuropathy > (CTCAE) grade 2
  • Patients receiving concurrent at the time protocol therapy is initiated other than for physiologic maintenance treatment
  • History of allergic reaction (including erythema nodosum) to lenalidomide
  • Concurrent use of complementary or alternative medicines that would confound the interpretation of toxicities and antitumor activity of the study drugs
  • Patients with to thromboprophylaxis
  • Unacceptable cardiac risk factors defined by any of the following criteria: patients with congenital long syndrome, any history of ventricular fibrillation or torsade de pointes, bradycardia defined as heart rate (HR) \< 50 bpm, \< 30%
  • Patients who have received targeted or agents within 2 weeks or within 5 half-lives of the agent and active metabolites (whichever is longer) and who have not recovered from side effects of those therapies
  • Patients who have undergone major surgery =\< 2 weeks prior to starting study drug or who have not recovered from the side-effects of surgery
  • Patients with known positivity for (HIV), or ; baseline testing for HIV and hepatitis C is not required
  • Patients with a history of another primary that is currently or currently requires active intervention, other than non-melanoma skin cancer and carcinoma in situ of the cervix should not be enrolled; patients are not considered to have a ?currently active? malignancy if they have completed therapy for a prior malignancy, are disease free from a prior malignancy for >= 5 yrs and are considered by their physician to be less than 30% risk of relapse
  • Patients with active (untreated or ) central nervous system (CNS) of the patient?s myeloma
  • Patients with a history of gastrointestinal surgery or other procedure that might, in the opinion of the investigator(s), interfere with the absorption or swallowing of the study drugs
  • Patients with any significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to them by the study staff
  • Any other medical condition, including mental illness or substance abuse, deemed by the investigator(s) to likely interfere with the patient?s ability to sign , cooperate and participate in the study, or interfere with the interpretation of the results
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Treatment (lenalidomide, nivolumab)

    Patients receive lenalidomide PO on days 1-21 and nivolumab IV over 1 hour on days 1 and 14. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

    Other: Laboratory Biomarker Analysis · Drug: Lenalidomide · Biological: Nivolumab · Other: Pharmacological Study

Interventions

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • Given PO

    Also known as: CC-5013, CC5013, CDC 501, Revlimid

  • BiologicalNivolumab

    Given IV

    Also known as: BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo

  • OtherPharmacological Study

    Correlative studies

06

What researchers measure

Primary outcomes

  1. ORR (Overall Response Rate)

    Will be assessed by IMWG response criteria. 95% binomial confidence intervals will also be calculated for the estimate of the proportion of responses.

    Time frame: Up to 12 months

Secondary outcomes

  1. Overall Survival (OS)

    Will evaluate other clinical outcomes using the methods of Kaplan-Meier.

    Time frame: Up to 3 years

  2. Progression Free Survival (PFS)

    Will evaluate other clinical outcomes using the methods of Kaplan-Meier.

    Time frame: Time from study entry until disease progression or death at trial closure for the per protocol population, assessed up to 3 years

  3. Time to Progression (TTP)

    Will be assessed.

    Time frame: Time from start of treatment until the date he or she has progression or dies, assessed up to 3 years

Other outcomes

  1. Immunomonitoring of Lymphocytes Subsets Including Natural Killer (NK) Cell

    Will be explored using graphical analyses as well as summarized quantitatively.

    Time frame: Up to 3 years

  2. Immunomonitoring of Lymphocytes Subsets Including T Cell

    Will be explored using graphical analyses as well as summarized quantitatively.

    Time frame: Up to 3 years

  3. Pharmacokinetics: The Maximum Plasma Concentration (Cmax)

    Will be assessed using Cmax for Nivolumab in combination with lenalidomide

    Time frame: Screening, days 1 and 14 of each cycle

  4. Pharmacodynamics Profiles:Time to Maximum Plasma Concentration (Tmax)

    Will be assessed using Tmax for Nivolumab in combination with lenalidomide

    Time frame: Screening, days 1 and 14 of each cycle

07

Results

Posted May 30, 2019
Limitations and caveats
Study was discontinued due to FDA recommendations of the potential toxities of the combination of nivolumab with an immunemodulator(lenalidomide, pomalidomde)

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Lenalidomide, Nivolumab)
Started1
Completed0
Not completed1

Outcome measures

PrimaryORR (Overall Response Rate)

Will be assessed by IMWG response criteria. 95% binomial confidence intervals will also be calculated for the estimate of the proportion of responses.

Time frame:
Up to 12 months

No measurements were reported for this outcome.

SecondaryOverall Survival (OS)

Will evaluate other clinical outcomes using the methods of Kaplan-Meier.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

SecondaryProgression Free Survival (PFS)

Will evaluate other clinical outcomes using the methods of Kaplan-Meier.

Time frame:
Time from study entry until disease progression or death at trial closure for the per protocol population, assessed up to 3 years

No measurements were reported for this outcome.

SecondaryTime to Progression (TTP)

Will be assessed.

Time frame:
Time from start of treatment until the date he or she has progression or dies, assessed up to 3 years

No measurements were reported for this outcome.

Other pre-specifiedImmunomonitoring of Lymphocytes Subsets Including Natural Killer (NK) Cell

Will be explored using graphical analyses as well as summarized quantitatively.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

Other pre-specifiedImmunomonitoring of Lymphocytes Subsets Including T Cell

Will be explored using graphical analyses as well as summarized quantitatively.

Time frame:
Up to 3 years

No measurements were reported for this outcome.

Other pre-specifiedPharmacokinetics: The Maximum Plasma Concentration (Cmax)

Will be assessed using Cmax for Nivolumab in combination with lenalidomide

Time frame:
Screening, days 1 and 14 of each cycle

No measurements were reported for this outcome.

Other pre-specifiedPharmacodynamics Profiles:Time to Maximum Plasma Concentration (Tmax)

Will be assessed using Tmax for Nivolumab in combination with lenalidomide

Time frame:
Screening, days 1 and 14 of each cycle

No measurements were reported for this outcome.

Adverse events

Collected over Adverse Events were collected up to 8 months during the study was conducted.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Lenalidomide, Nivolumab)0/1 (0%)0/1 (0%)1/1 (100%)
Most frequent other events
Showing 10 of 27
Most frequent other events
EventTreatment (Lenalidomide, Nivolumab)
AnemiaBlood and lymphatic system disorders1/1
AnorexiaMetabolism and nutrition disorders1/1
Aspartate Aminotransferasae IncreasedInvestigations1/1
Blood Bilirubin IncreasedInvestigations1/1
Cognitive DisturbanceNervous system disorders1/1
Cough (non-productive)Respiratory, thoracic and mediastinal disorders1/1
Diarrhea-intermittentGastrointestinal disorders1/1
Dry Skin- Bilateral Lower ExtremitiesSkin and subcutaneous tissue disorders1/1
DyspneaRespiratory, thoracic and mediastinal disorders1/1
Eye HemorrhageEye disorders1/1

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Lenalidomide, Nivolumab)
<=18 years0
Between 18 and 65 years0
>=65 years1
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Lenalidomide, Nivolumab)
Female0
Male1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Lenalidomide, Nivolumab)
Hispanic or Latino0
Not Hispanic or Latino1
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Lenalidomide, Nivolumab)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White1
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(participants)Treatment (Lenalidomide, Nivolumab)
United States1
08

Study locations

1 site
  • Ohio State University Comprehensive Cancer Center
    Columbus, Ohio 43210, United States
09

References and documents

Related links

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2018 to primary completion in Aug 2018, 4 months.

Results were first posted in May 2019, 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Nov 7, 2017
StartActual
Mar 21, 2018
Primary completionActual
Aug 13, 2018
CompletionActual
Nov 16, 2018
Results first posted
May 30, 2019
Last update
May 30, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 30, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03333746
Lead sponsor
Yvonne Efebera
Collaborators
National Cancer Institute (NCI), American Cancer Society, Inc., Bristol-Myers Squibb
Responsible party
Yvonne Efebera (Principal Investigator, Ohio State University Comprehensive Cancer Center) — Sponsor-investigator
First posted
Nov 7, 2017
Start date
Mar 21, 2018
Primary completion
Aug 13, 2018
Completion
Nov 16, 2018
Results posted
May 30, 2019
Last update
May 30, 2019

Study contacts

Yvonne Efebera, MD
principal investigator · Ohio State University Comprehensive Cancer Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lenalidomide · Nivolumab

Start the discussion